"Ziba offered a turn-key development process, from design, to engineering, to prototyping, to user testing... They really understood our needs as a startup."
Different war; different wounds.
Bleeding to death remains a leading risk for soldiers on the battlefield, despite improvements in body armor. During the second war in Iraq, the US military was struggling to deal with an onslaught of deep wounds in impossible-to-tourniquet locations. Injuries like these can cause hemorrhage and death in less than 90 seconds. RevMedx found a new first aid solution by combining an advanced compound with compressed sponges. Together, these two technologies can stop bleeding in seconds, even when an artery is ruptured. Medics wanted a “...fire and forget solution – essentially Fix-A-Flat® for wounds,” according to John Steinbaugh, U.S. Army Special Forces medic (retired) and Vice President for Strategic Development at RevMedx. Medics like Steinbaugh said that saving the lives of soldiers with hemorrhaging wounds require both hands and 100% of their attention. XStat changed that, freeing them to provide care to other wounded soldiers or return to combat with their units. Ziba helped RevMedx design a way to deliver these sponges deep inside wounds – fast.
XStat is so different from any wound dressing available before that the FDA created a new category leading up to its April 2014 approval for battlefield use. Since, it's also been approved by the FDA for use on the general civilian population. It’s attracted attention from beyond military and first-responder communities, with writeups in publications from Wired to the Daily News, an appearance on CBS This Morning, and a Popular Science Invention Award win. An analyst for Wall Street Daily wrote “RevMedx’s patent-pending products will serve as the latest proof that simple technology can be truly disruptive.”
“Ziba offered a turn-key development process, from design, to engineering, to prototyping, to user testing – which was huge for the military – to injection molding and production oversight. They really understood our needs as a startup,” said Paul Longo, RevMedx VP for Product Development.